MatTek Life Sciences

MatTek Life Sciences is a biotechnology company specializing in tissue engineering and in vitro science, providing innovative solutions for safety and efficacy testing in pharmaceuticals and cosmetics. MatTek Life Sciences, founded in 1985 in Ashland, US, focuses on developing human tissue models for research. The firm has maintained its core business strategy over the years without significant pivots. It operates globally, with its headquarters in Ashland and has conducted 1 deal, with the most recent deal occurring on April 4, 2025.

In the latest funding round, Sartorius AG invested USD 80 mn to enhance its cell culture technologies. MatTek Life Sciences specializes in developing innovative biotechnology solutions centered around tissue engineering and in vitro science. The company’s core offerings include a range of tissue models that utilize primary human cells to provide platforms for predictive human biology. These models address various applications, including skin irritation testing, ocular toxicity assessments, and drug delivery evaluations.

MatTek's products, such as EpiAirway™ and EpiDerm™, are designed to simulate human organ systems, making them vital for pharmaceutical and cosmetic companies conducting safety and efficacy testing. The customer base primarily consists of pharmaceutical and biotech firms, academic institutions, and research organizations in North America, Europe, and Asia, reflecting the global applicability of their products. MatTek Life Sciences generates revenue through direct sales of its specialized tissue models, cultureware, and associated services to a diverse clientele in the pharmaceutical and biotech sectors. Transactions typically occur through B2B contracts, where clients purchase products for research and development purposes.

The company may offer structured pricing plans based on volume and specific product lines, facilitating bulk purchases for larger organizations. Flagship products, such as the EpiDerm™ model, form a significant part of the revenue stream, catering to clients who require reliable in vitro testing solutions. With a strong focus on customer satisfaction and innovation, MatTek aims to solidify its position in the market through strategic partnerships and collaborations. In April 2025, MatTek Life Sciences plans to leverage its recent funding of USD 80 mn from Sartorius AG to further develop its cell culture technologies.

The company is focused on launching new products designed to enhance its tissue models and expand its market presence, targeting new geographic regions in Asia and Europe by 2026. This strategic growth is aimed at enhancing its product offerings and reaching a broader clientele in pharmaceutical and biotech industries.